Article Text

Download PDFPDF
Unexplained illness and deaths among injecting drug users in England: a case control study using Regional Drug Misuse Databases
  1. M A Bellisa,
  2. C Beynona,
  3. T Millarb,
  4. J R Ashtonc,
  5. R Thomsond,
  6. T Djuretice,
  7. A Taylorf
  1. aNorth West Public Health Observatory, Public Health Sector, Liverpool John Moores University, L3 2AB, UK, bThe Drug Misuse Research Unit, (University of Manchester), UK, cNHS Executive North West, Birchwood, UK, dSefton Health Authority, Sefton, UK, eCommunicable Disease Surveillance Centre, Public Health Laboratory Service, Colindale, UK, fScottish Centre for Infection and Environmental Health, Glasgow, UK
  1. Professor Bellis (m.a.bellis{at}livjm.ac.uk)

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In April to June 2000 an outbreak of unexplained illness in injecting drug users (IDUs) in parts of the UK led to hospitalisation and usually death among those affected.1 For investigation purposes a new syndrome-based case definition was constructed as, extensive inflammation at a subcutaneous or intramuscular injection site and, either severe system toxicity or, postmortem evidence of a diffuse toxic or infectious process.2 Between 1 April and 19 June investigation of 88 hospitalised or dead IDUs with injection site soft tissue inflammation found 35 met the case definition. Despite very high mortality (34, 97%) only limited epidemiological information is available.1 However, empirical evidence identifying the characteristics of IDUs most at risk is fundamental to, better understanding the outbreak, preventing re-occurrence and developing appropriate advice should one occur in the UK or elsewhere.

By the end of June, 14 confirmed cases (12 fatal) were identified in the …

View Full Text

Footnotes

  • Funding: none.

  • Conflicts of interest: none.